Hormone deficiency and cardiovascular disease: clinical impact, treatment strategies and prognostic prediction

Despite advances in hormone replacement, many patients retain excess CV risk that is not captured by conventional prediction models. Endocrine-adapted risk stratification, individualized replacement strategies considering dose and chronobiology, and integration of emerging tools such as artificial intelligence - based models may improve risk prediction. Dedicated cardiovascular outcome trials in endocrine populations remain a major unmet need.